Re: Hopefully DM's exuberance is justified in the secondary endpoints

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

chicagoest

Rank: President [?]

Points: 1974 [?]

Votes: 20 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Hopefully DM's exuberance is justified in the secondary endpoints

in response to

Re: Hopefully DM's exuberance is justified in the secondary endpoints

BearDownAZ

posted on Nov 18, 2019 05:09PM

BDAZ

Thanks and sorry about that - It's old news now

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply